Category: Uncategorized

The Food and Drug Administration (FDA) recently announced a new guidance program for the life science industry regarding data integrity. This FDA guidance draft is currently open & available for the industry to comment on and provide feedback. Additionally, the FDA regulatory process that looks to be initially targeted by the food and drug authority includes:

 

  • Investigational New Drug Application (IND)
  • New Drug Application (NDA)
  • Abbreviated New Drug Application (ANDA)
  • Biologic License Application (BLA)

 

Code of Federal Regulations

 

The guidance draft cites several different code of federal regulation (CFR) that are being reviewed and analyzed during this process. Specific CFR federal regulations mentioned include:

 

  • 21 CFR 11
  • 21 CFR 50
  • 21 CFR 56
  • 21 CFR 58
  • 21 CFR 210
  • 21 CFR 211
  • 21 CFR 312
  • 21 CFR 601
  • 21 CFR 820

 

Data Integrity

 

Specific use cases mentioned by FDA include data integrity throughout the clinical data management process in bioavailability (BA) & bioequivalence (BE) studies. Further, the FDA guidance provides initial suggestions to optimize data integrity success by focusing on three specific drivers:

 

  • Users or applicants in clinical trial
  • Site management of clinical trial
  • Quality management system for clinical trial

 

Finally, FDA provides best practices & recommendations for risk control and risk management. Understanding how to maintain good lab practice & clinical research success is essential for all participants.

 

FDA Guidelines

 

One of the primary objectives of the data integrity draft is to align FDA expectations with the clinical data being submitted in pharmacologic studies. Additionally, clinical data submitted by a drug sponsor for FDA drug approval must be:

 

“accurate, complete, and reliable, and that industry maintain data integrity throughout the data lifecycle of the product(s) or biologic therapeutic(s).”

 

Finally, new concerns are being raised about the evaluation of bioequivalence and bioavailability study data submitted during the FDA regulatory process. FDA highlights specific comments about regulatory concerns during in vivo pharmacology studies. The regulatory documentation lists specific areas adding to the erosion of data integrity based on FDA inspection experiences in the field:

 

  • Patient testing sites
  • Clinical testing sites
  • Analytical testing sites

 

Legal Regulation

 

The FDA guidance begins with reminding drug sponsors that they bear the responsibility of quality assurance even if a contact manufacturing organization (CMO) is engaged. Additionally, confirming a contract development and manufacturing organization (CDMO) has confidentiality processes in place is essential. 

 

For drug sponsors who are submitting a FDA new drug application, ICH guidelines and FDA guidance should be followed by external vendors who are conducting the elements of study-related activity. Finally, clinical data being generated through bioavailability and bioequivalence studies must be durable & reliable in nature, and properly documented in a quality management system (QMS).

 

Testing Site

 

The regulatory guidance goes on to elaborate about the monitoring and oversight strategy needed for clinical testing. Specific drivers listed for analysis when selecting a drug manufacturing partner include:

 

  • Personnel Education
  • Personnel Experience
  • Personnel Training

 

Manufacturing standards and expectations should be documented clearly in a formal agreement. Additionally, FDA highlights that regulatory requirements for clinical study activities should be documented and followed, including:

 

  • Clinical study protocol
  • Clinical study procedure
  • Clinical study process

 

Finally, FDA recommends that bioanalytical analysis should include closer oversight and monitoring. Any CMO or CDMO must have documented analytical methods in their quality management system. Further, all analytical methodologies must follow applicable FDA regulations and be included in the QMS standard operating procedures (SOP).

 

Quality Management System

 

The FDA guidance transitions to describe database integrity and why any clinical services provider you choose must “use a quality management system to help ensure data integrity”. This includes testing sites managing a quality management system and efficacy of “data governance throughout the data lifecycle”.

 

Records Management

 

The operations team supporting the clinical research management should review the QMS using a pre-planned schedule, per the FDA guidance. All data governance used to store and retrieve information in the clinical trial management system should replicate the reliability & durability of the QMS. 

 

Additionally, data integrity across the QMS would focus on each unique phase of the collection process. FDA recommends employees responsible for quality updates consider isolating job responsibilities between the separate data lifecycle phases to help reduce unintentional mishaps.

 

Clinical Technology

 

Using modern technology is recommended for all employees who are responsible & can impact data quality. Specific systems mentioned in the regulatory guidance that can improve data integrity include:

 

  • Computer hardware or related systems
  • 362 software for security or performance
  • Peripheral devices, networks or cloud infrastructure for connectivity
  • Any associated IT documents for usability (e.g. SOP manual)

 

Metadata

 

The guidance goes on to explain more about classification & ensuring that metadata is correct. Metadata, as described by FDA, is “data about data” and provides clarifying information to the agency. Common types of metadata quality concerns are listed as examples:

 

  • Missing date/time stamp for when data was acquired
  • Incorrect measurement units or documentation
  • Missing user ID’s of the team who conducted data testing or data analysis

 

Sample Analysis

 

An important facet of the FDA guidance discusses sample analysis & if the clinical evaluation is completed at a location different from the original testing site. Employees conducting the clinical evaluation should be familiar with good clinical practice & fully understand the study protocol, various test methods that were used, and any quality management system SOPs to follow.

 

Further, different types of instruments & clinical equipment used during the sample analysis should be “calibrated, maintained and serviced” per FDA. The regulatory guidance cites several examples that should follow manufacturer service guidelines, including:

 

  • Balances & pipettes
  • Centrifuges & spectrometers
  • Liquid chromatographs
  • Refrigerators & storage freezers

 

Quality Assurance and Quality Control

 

Managing the risk associated with a QMS is an important facet of the FDA guidance. A quality assurance program should be implemented, including standard operating procedures that limit access control & processes to isolate a data breach. Further, implementing a quality control program can help find and remedy data integrity flaws. An efficient quality control program should include:

 

  • Mapping of standard processes & risk control
  • Employee training & knowledge gaps
  • Difference between unintentional & intentionally compromised data

 

Corrective Action and Preventative Action

 

If data integrity deviations are identified in a quality control analysis, FDA recommends a corrective and preventative action (CAPA) program be launched. Additionally, the CAPA would look at all relevant processes and tasks as a whole rather than isolating a repeat occurrence. The recommended best practices for a quality control plan include:

 

  • Assemble & examine information for review
  • Identify real & possible problems during the review
  • Explore problems & create appropriate CAPA
  • Verify & validate the success of the CAPA
  • Communicate updated CAPA success to applicable teams
  • Document activity & intelligence for management review

 

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

The U.S. Food and Drug Administration (FDA), Health Canada, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) have recently identified 10 guiding principles for the development of Good Machine Learning Practice (GMLP).

 

These guiding software development principles should be used to:

 

  • Adopt good practices that have been proven in other sectors
  • Tailor practices from other sectors so they are applicable to medical technology and the health care sector
  • Create new practices specific for medical technology and the health care sector

 


Need help putting these principles into action? Talk to our Experts →


 

What is Artificial intelligence and FDA machine learning (AI/ML)?

Artificial intelligence and machine learning use software algorithms to learn from real-world use of the device to help improve the product’s performance.

 

Good Machine Learning Practice Guiding Principles

 

  1. Multi-Disciplinary Expertise Is Leveraged Throughout the Total Product Lifecycle. Helps ensure that ML-enabled medical devices are safe and effective and address clinically meaningful needs over the lifecycle of the device.
  2. Good Software Engineering and Security Practices Are Implemented. Implementation with attention to the “fundamentals”: good software engineering practices, data quality assurance, data management, and robust cybersecurity practices.
  3. Clinical Study Participants and Data Sets Are Representative of the Intended Patient Population. Manage bias, promote appropriate and generalizable performance across the intended patient population, assess usability, and identify circumstances where the model may underperform.
  4. Training Data Sets Are Independent of Test Sets. Training and test datasets are selected and maintained to be appropriately independent of one another.
  5. Selected Reference Datasets Are Based Upon Best Available Methods. Using the best available methods for developing a reference dataset ensures that clinically relevant and well-characterized data is collected and the limitations of the reference are understood.
  6. Design Is Tailored to the Available Data and Reflects the Intended Use of the Device. Design is suited to the available data and supports the active mitigation of known risks, like overfitting, performance degradation, and security risks.
  7. Focus Is Placed on the Performance of the Human-AI Team. Human factors considerations and human interpretability are addressed with emphasis on the performance of the Human-AI team.
  8. Testing Demonstrates Device Performance during Clinically Relevant Conditions. Developed and executed statistically sound test plans to generate clinically relevant device performance information independently of the training data set.
  9. Users Are Provided Clear, Essential Information. Users are provided ready access to clear, contextually relevant information that is appropriate for the intended audience.
  10. Deployed Models Are Monitored for Performance and Re-training Risks are Managed. Models have the capability to be monitored in “real world” use with a focus on maintained or improved safety and performance, as well as periodic training after deployment.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

The US Food and Drug Administration (FDA) recently issued final guidance for Biologics industry executives to help define modifications to existing products and update submission procedures.  The primary focus of the guidance is to help biologics industry employees responsible for reporting understand which type of risk category is appropriate for updated variations in chemistry, manufacturing, and controls (CMC).

 

The guidance is applicable to CMC products with an existing biologics license application (BLA) currently approved by the FDA. It’s a critical update since any Biologics company or regulatory partners must notify the FDA about every change to an approved BLA under the Code of Federal Regulations (21 CFR 601.12).


Need help adhering to the New Guidance? Contact Us Now →


FDA submission data

 

FDA Guidance

The final FDA guidance goes into detail about each post-approval change in the product, including production process, quality controls, equipment and facilities, responsible employees, and established labeling. Expanded submission data will potentially provide greater detail about the the risk profile related to the changes, and how revised changes impact the intended safety or efficacy of the product.

 

Assessing and implementing manufacturing changes is laid out in great detail in the FDA guidance. Comparability data will be used to show variations of the product pre- and post- changes. The comparability analysis is necessary to help gauge possible effects of the product changes. Data from the analysis will be represented through a variety of sources, including a combination of testing, validation studies, and non-clinical or clinical studies.

 

FDA submission procedure

 

More importantly, the guidance provides a greater amount of detail about the updated FDA submission procedure. A significant focus of the guidance acknowledges the opportunity for adverse effects and how to measure and minimize based on data about the revised formulation. The biologic submission must show reference information that considers the new identity, strength of the product, quality of the product, and purity or potency of the product.

 

The three unique types of Biologics reporting includes Prior Approval Supplement, Changes Being Effected in 30 Days/Changes Being Effected (CBE30/CBE) and an Annual Report:

 

Prior Approval Support (PAS)

  • This includes changes that have significant potential for an adverse effect on product quality. The PAS must be approved by the FDA before a Biologics company can distribute any updated BLA approved product to the market involving the changes.

 

Guidance Changes Being Effected in 30 Days/Changes Being Effected (CBE30/CBE)

  • This includes changes that have a moderate potential to have an adverse effect on product quality. The CBE30/CBE requires an applicant to report the change to the FDA in a supplement at least 30 days before distribution of the product to the market.

 

Annual Report (AR)

  • This includes changes that have a minimal potential to have an adverse effect on product quality.

 

FDA process validation

 

Assessing the impact of the change on product quality is critically important in the reporting submission.  Reporting data should include prior knowledge and findings from product development activity. Documentation surrounding process validation activities and manufacturing expertise of the approved BLA product are also requested.

 

Quality risk management activities or pre-commercial studies that provide expanded awareness of the effects of the changes can also be very valuable for FDA decision makers. Finally, a cumulative impact assessment of multiple changes on the updated BLA product can help ensure post-market surveillance activities are aligned between the FDA and Biologics company.

 

Quality Management System

 

References to a robust quality culture appear throughout the guidance, including developing of robust manufacturing processes and process controls. Innovative process validation techniques and analytical testing are listed as critical drivers Biologics companies should practice to help mitigate risks associated with manufacturing changes.

 

Having an effective quality risk management system allows Biologics industry executives to make knowledgeable choices regarding manufacturing variations. The quality system data increases the confidence of product quality and process consistency for both executives and the FDA. Formal and informal risk assessments to support of post-approval manufacturing changes increases the accuracy of a more effective assessment of the change, which can increase the speed of the FDA’s decision.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

The U.S. Food and Drug Administration (FDA) held a public meeting in May 2019 to get comments and feedback about the making, marketing, sale and promotion of products with CBD (cannabidiol). The meeting generated much interest from businesses in the cannabis, cannabidiol and marijuana industry, with many wondering what new cannabis regulation may arise from those open meetings.

 

There is no doubt cannabis is a growing industry, with many states already legalizing the use of CBD and related products. As the industry evolves, there is more interest at the federal, state and consumer levels to regulate the industry. In November 2019 alone, there were 137 bills at the state level being considered for regulating hemp derivative and CBD products. Bipartisan efforts at the federal level have been calling for more controls, as have consumer groups.

 

Preparing for Regulations

 

There are a few things companies can do to prepare themselves for changes in this regulatory environment:

 

  • Read up: The FDA has information on their website, and there are industry publications trying to stay current with rules and regulations. It can be challenging to know where to start, especially since there are so many sources and so much information. Nevertheless, reading can give you some overall impressions of regulatory trends.
  • Look at current guidelines: You need to stay current with drug regulations for tracking, manufacturing and distribution. You will also want to use the Current Good Manufacturing Practice (CGMP) regulations set by the FDA to compare with your own processes and products. The CGMP rules are guidelines created for products that transform botanicals to drug products, so they apply to CBD and cannabis products.
  • Create controls: Create consistent products and take the time to develop quality control processes. Create documentation systems so you always have the data you need to meet current regulatory guidelines. Current drug regulations place great emphasis on processes for quality control, so it makes sense to put extra focus on this area.

 

FDA Cannabis Regulations

 

The FDA is currently focusing on marketing language of cannabis-related products. In fact, the agency is sending out warning letters to companies making such products, in some cases based only on a business’s marketing strategy. For instance, the Federal Trade Commission sent one of those letters to a company that was claiming the CBD products they were offering were “proven” treatments for AIDS, autism and other conditions. In addition, the FDA has been warning the public about misleading or inaccurate claims of cannabis products.

If you make a product with CBD or cannabis and are considering any health claims for your product, be extra vigilant. Make sure you have the research and tests to back it up and work to create controls. Keep strict documentation on all your processes, marketing efforts and testing.

 

Cannabis Regulation

 

Developing solutions for regulation challenges does not have to be complicated in the cannabis industry. Regulatory Compliance Associates works with companies, helping them stay compliant. In the face of changing FDA regulations, we help you resolve regulatory and quality issues. Contact us at Regulatory Compliance Associates to find out more.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

To learn more about quality control and data integrity, you need to understand what these terms mean and how they can affect your company.

 

What Is Quality Control and Data Integrity?

 

The Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments document from PICS offers perhaps the most comprehensive explanation of what a quality culture is. According to that document, this type of culture is a work environment that is open and transparent, allowing team members to fully and openly communicate mistakes and failures. This open culture is also a work environment where there are processes and structures that allow information about mistakes and problems to flow between team members at different levels.

 

Why Quality Culture?

 

Quality culture and its importance to the World Health Organization, MHRA and PICS recognizes that data quality is reliant on type of workplace. An organization that punishes team members who come forward with mistakes or issues is likely to have fewer reportable issues and less transparency, which can mean less accurate data. By allowing team members to speak freely and permitting the information to flow to different tiers of the organization, you’ll ensure that data can be accurately collected and acted upon.

 

Improving Organizational Quality Culture and Data Integrity through Risk Management

 

If you would like to create a quality culture, your organization can take several steps, including:

  • Creating a quality risk management plan: A written quality risk management plan should include your potential risks and a detailed plan on how to address problems and mistakes. This plan should make it clear that every team member is part of the solution and can report problems without risk of retaliation.
  • Evaluating your risks: Run an organization-wide audit to evaluate which risks could negatively impact product quality. As you start to write your quality risk management plan, begin by evaluating the risks that could impact your product. Could a supplier issue compromise the product? What other problems have arisen in the past or affected others in your industry?
  • Having a remediation plan: Create a written plan on what to do if something happens. How will an issue be reported? Once an issue is reported, what will the next steps be? How can you begin the remediation process?
  • Maintaining your plans as living documents: The goal of a quality risk management plan isn’t to create a document that sits on a computer. Present the document to your team and use it every day. Add to the document as new challenges come to light, and encourage your team to abide by the plan.

 

How We Can Help

 

A quality culture will help you pave the way for success because you’ll be enjoying better data. When you need to submit to global regulatory agencies, having more robust data can also help.

 

While having data integrity and good metrics is a crucial factor for biologics, medical device, pharmaceutical, compounding pharmacy and other organizations, an open quality culture is also important. In addition, it will help you to notice issues and address them in a timely fashion as well as enable you to plan what to do when problems arise.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Amanda Pedersen, senior editor for MD+DI magazine, interviewed Susan Schniepp, Troy Fugate, and Steven Niedeleman to discuss “some of the craziest things FDA investigators hear during a US FDA inspection”. Below is an excerpt of her widely circulated column. 

 

One pearl of wisdom I often hear from regulatory and quality experts on the subject of managing FDA inspections is to answer the investigator’s questions and then zip it – do not offer more information than what is asked. For this reason alone, I would be a terrible “front room” person during an FDA inspection.

 

While I typically work best under pressure, uncomfortable silence is my kryptonite. I can easily see myself getting nervous and word-vomiting all over the investigator. There’s been a rash of medical device recalls and regulatory snafus in recent weeks, so it seems like a good time for some tried and true tips for interacting with FDA. 

 

1. “You don’t know what you’re talking about.”

 

It should go without saying, but never argue with the FDA investigator or insult their intelligence. It’s not going to lead anywhere good. If you do happen to find yourself in a disagreement during the inspection, do your best to de-escalate the situation. Whatever you do, don’t choose violence.

 

Troy Fugate, co-founder and vice president at Compliance Insight, recently shared a wild story from the field about an FDA inspection at a foreign site that went horribly wrong. The plant manager didn’t like that the investigator was finding problems and a heated argument ensued. The plant manager became so angry that he punched the investigator in the face.

 

2. “During the last inspection, the FDA investigator saw the same thing and did not put it on the Form 483.”

 

That would be like telling a police officer that you’ve been pulled over before for the same violation, but you got off with a warning. Don’t expect the investigator to second-guess their FDA 483 observation just because you got away with the same issue in the past.

 

3. “The last investigator was crazy.” Or “The last investigator did not know what they were doing.”

 

Best case scenario, the FDA investigator agrees with you, but wonders if you’ll badmouth them during your next US FDA inspection. Worst case, you just insulted their favorite colleague.

 

4. “I told them not to do it this way…”

 

Don’t be that person. Present a united front as a company and simply acknowledge the issue and express a willingness to address it. Don’t throw your colleagues under the bus in front of FDA because you’re only going to make yourself look bad.

 

5. “The management of this firm is only concerned with profits and does not take quality seriously.”

 

Even if this is true, nothing good will come from sharing the company’s dirty laundry with FDA. If you have legitimate concerns about your firm’s quality assurance, there is surely a more appropriate time and place to bring it up than during an FDA inspection. If your concerns get brushed off, maybe consider going the whistleblower route.

 

6. “We don’t have enough people or time to review all those complaints…”

 

Manufacturers must prioritize their resources. Being a small or understaffed company is no excuse to turn a blind eye to quality complaints, especially in medtech where people’s lives may be at stake. Don’t waste time during an FDA inspection trying to justify poor handling of complaints.

 

7. “That is the way we have always done it.”

 

If I was an FDA investigator, this sad excuse for any FDA observation, however big or small, would make me wonder what other procedures the manufacturer has “always” done the wrong way.

 

8. “That’s not my fault. It was the previous person who did that…”

 

Don’t point fingers. It’s childish and annoying. The investigator doesn’t care whose fault something is, they just want it fixed.

 

9. Don’t lie to FDA … but that doesn’t mean you should have to put such a statement in writing anywhere that an FDA investigator might see it.

 

This one comes from an embarrassing story Susan Schniepp of Regulatory Compliance Associates shared with Medtech Insight a few years back. She had just started working as VP of a small company when FDA came knocking. The company’s director of quality handled the audit while Schniepp observed. The director proudly handed the investigator the company’s standard operating procedure (SOP) document on how the firm handled inspections. That seemed like a great first step until she saw the line on the SOP that read: Don’t lie to the FDA.

 

As Schniepp said, surely the FDA investigator wondered exactly what the firm is doing the rest of the time that it needs to remind its employees not to lie to FDA. So, she said, FDA inspections are all about perception and putting the company’s best foot forward, so to speak. Don’t write SOPs like you’re reading them, she advised, but like someone else is going to read them. But it wouldn’t be fair to point out all the ways manufacturers have screwed up during FDA audits without acknowledging that FDA inspectors are human too and have been known to act inappropriately and even downright creepy at inspection sites.

 

Click now to read the full article here.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].